A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability and Immunogenicity of Heterologous Prime-Boost Regimens Using MVA-BN-Filo and Ad26.ZEBOV Administered in Different Sequences and Schedules in Healthy Adults

Trial Profile

A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability and Immunogenicity of Heterologous Prime-Boost Regimens Using MVA-BN-Filo and Ad26.ZEBOV Administered in Different Sequences and Schedules in Healthy Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Ad26 EBOV vaccine (Primary) ; Modified Vaccinia Ankara Bavarian Nordic Ebola Marburg vaccine (Primary)
  • Indications Ebola virus infections; Marburg virus disease
  • Focus Adverse reactions; First in man
  • Sponsors Crucell Holland
  • Most Recent Events

    • 28 Apr 2016 According to Janssen media release, in the open label part of the study, subject of follow-up in eight months after the test was completed in October 2015 and additional analysis in the 12 months after the study is currently being carried out.
    • 28 Apr 2016 Results published in Janssen media release.
    • 19 Apr 2016 Results published in a Bavarian Nordic media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top